A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults with Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies

Inclusion Criteria:
*  Age ≥ 18 years up to ≤ 75 years at the time of informed consent
*  Confirmed diagnosis of melanoma, non-small cell lung cancer (NSCLC), or colorectal cancer (CRC) that is metastatic or locally advanced or unresectable and is relapsed and/or refractory (R/R) after standard therapy for each tumor histology
*  Participants must have received prior systemic treatment for their metastatic disease or locally advanced disease based on tumor type as follows:
*  Melanoma: participants with disease progression following an immune checkpoint inhibitor (CPI)
*  NSCLC: participants with disease progression following at least 1 approved systemic therapy, including an immune CPI-containing regimen for appropriate patients or an approved targeted therapy for known molecular abnormalities if applicable to their disease
*  CRC: participants with disease progression following at least 1 line of therapy, including a fluoropyrimidine with oxaliplatin or irinotecan. Microsatellite instability (MSI) high/mismatch repair deficient (dMMR) CRC participants must have disease progression following systemic therapy with immune CPIs.
*  Measurable disease including at least 1 lesion that is safely resectable AND a target lesion to measure response and an additional lesion for biopsy
*  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
*  Adequate organ and marrow function
*  Women of childbearing potential must have a negative pregnancy test at screening
*  All participants must agree to practice highly effective methods of contraception
*  Fully recovered from toxicity from prior systemic anticancer therapy

Exclusion Criteria:
*  Prior treatment with adoptive cellular therapy
*  Prior solid organ transplantation
*  Central nervous system (CNS) involvement of disease that is extensive, symptomatic or untreated, or patients with leptomeningeal disease
*  Uncontrolled or symptomatic pleural effusion or ascites
*  Untreated or active systemic infection
*  Active autoimmune disease requiring treatment or primary immunodeficiency syndrome
*  Systemic corticosteroids at a dose of \>10 mg of prednisone or equivalent per day
*  Other primary malignancy within 3 years prior to enrollment
*  Impaired cardiac function or clinically significant cardiovascular disease
*  Required chronic anticoagulation, such as warfarin, low molecular weight heparin, or Factor Xa inhibitors
*  Pregnant or nursing (lactating) women